mTOR inhibitor; inhibits tumor growth in breast cancer cell lines (IC50
values are 1.6 and 4.3 nM for SKBr3 and BT474, respectively). Inhibits HIF-1α
-mediated VEGF production in breast cancer cell lines (BT474 and MDA-MB-231). Directly inhibits serum and VEGF mediated endothelial cell proliferation and morphogenesis in vitro
and vessel formation in vivo
. Causes G1
/S cell cycle arrest in multiple cancer cell lines. Antiangiogenic.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Del Bufalo et al.
Cancer Res., 2006;66:5549
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L et al.
Cancer Res., 2005;65:2825
The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells.
Li et al.
Cancer Cell Int., 2013;13
Inhibition of mammalian target of rapamycin signaling by CCI-779 (temsirolimus) induces growth inhibition and cell cycle arrest in Cashmere goat fetal fibroblasts (Capra hircus).
Wang et al.
DNA Cell Biol., 2012;31:1095